EnWave Corporation

EnWave Corporation

December 16, 2010 06:30 ET

EnWave Announces Positive Animal Vaccine Dehydration Results and New Testing Agreement with Saskatchewan Research Council

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 16, 2010) - EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company") today announced that the Saskatchewan Research Council ("SRC") has demonstrated positive results in a set of viability and shelf-life tests designed to measure the potential benefits of EnWave's freezeREV™ Radiant Energy Vacuum ("REV") dehydration technology over the standard industry method for preserving pharmaceuticals in-vial, freeze drying. Conducted at the SRC Fermentation Pilot Plant in Saskatoon, Saskatchewan, on a live Escherichia coli ("E.coli") animal vaccine, the tests showed that the freezeREV™ single-vial prototype is capable of drying this vaccine in 50 minutes compared to 40 hours of freeze drying, with the same bacterial survival rates.

Following the successful dehydration test, samples were then placed into a six month shelf-life study at three different temperatures 4°C, 22°C and 37°C (39.2°F, 71.6°F and 98.6°F) to measure organism survival over time. Results from the study have shown that the freezeREV™ process is comparable to freeze drying, although survival rates were lower with the freezeREV™ samples stored at the highest temperature. Scientists from both SRC and EnWave believe that this result can be improved by making adjustments to the design of the technology, and the two companies have now signed a Testing Agreement ("the Agreement") to collaborate on the further development and testing of EnWave's recently announced multi-vial freezeREV™ prototype.

"SRC is very pleased with these results as they show promise for the pharmaceutical industry that so clearly needs to improve the speed and effectiveness of its current method of preserving vaccines for shipment and storage," said Dale Kelly, Vice-President of SRC's Agriculture, Biotechnology and Food Division. "EnWave's freezeREV™ is an excellent example of Canadian ingenuity and innovation at work, and our organization is keen to move to the next step with EnWave in developing this exciting technology."

"Over the past three years, freezeREV™ has shown a great deal of promise as a high-speed dehydration method for a wide variety of biomaterials in vials including bacteria, enzymes, antibodies and viruses," said Dr. Tim Durance, EnWave's Chairman and Co-CEO. "I am very much looking forward to the next stage of development for this technology, and to continuing our productive and cost-effective relationship with SRC."

EnWave's proprietary Radiant Energy Vacuum ("REV") technology combines microwave energy with vacuum pressure to produce high-speed dehydration of live or active pharmaceuticals and other biomaterials stored in vials. The Company has developed two versions of REV for this sector: bioREV™, a dehydration method for materials which require a gentler drying process without extreme temperature changes or freezing, and freezeREV™, an accelerated freeze drying method for material where low moisture levels in the final product are imperative for long product shelf-life.

About SRC

SRC is Saskatchewan's leading provider of applied R&D and technology commercialization. It takes the leading-edge knowledge developed in Saskatchewan and sells it to the world and, at the same time, brings the best knowledge the world has to offer and applies it to unique Saskatchewan situations. SRC, a Treasury Board Crown Corporation, was established in 1947 to advance the development of the province in the physical sciences. Today, SRC has evolved to become a market-driven corporation, selling sevices and products to companies in Saskatchewan and around the world. The company currently has more than 400 employees. Annual revenues are over $42.6 million and growing. More information is available about SRC at www.src.sk.ca.

About EnWave

Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is commercializing a new method for dehydrating food and biological materials using Radiant Energy Vacuum ("REV") technology under its nutraREV™, powderREV™, bioREV™ and freezeREV™ brands. REV technology combines microwave energy transfer under vacuum to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and medical applications that include fruit, vegetables, probiotics, enzymes, proteins, food cultures, vaccines and antibodies. More information about EnWave is available at www.enwave.net.

EnWave Corporation
John McNicol
President & Co-CEO

Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. There is no guarantee that transactions contemplated under the agreements for the acquisition of the Intellectual Property will close, there is no guarantee the Company's REV technology can or will improve processes in the target industry; even if the Company's REV technology can be used as described in this document, there is no guarantee that such use will result in orders for the Company's REV technology. All figures comparing REV technologies to freeze drying or other dehydration technologies are provided as examples of data obtained through the Company's own scientific and testing programs; each product must be tested individually to determine the benefits of using REV.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information